Welcome to the e-CCO Library Archive!

Filter:
DOP084.

An accelerated infliximab dosing strategy for rescue therapy in acute severe colitis is associated with reduced early colectomy rate

Authors:

D.J. Gibson, Z. Heetun, K. Byrne, D. Keegan, G. Cullen, H. Mulcahy, G.A. Doherty, St. Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland

DOP084

Interpreting genetic variants in IBD as quantative immune traits by the assessment of cytokine profiles

Authors:

N. Duijvis1, 2, G. D'Haens*3, A. te Velde2, F. van Dooren2, D. Oudejans2, S. Keskin2, S. Wolfkamp2, E. Vogels2, P. Henneman2, G. D'Haens3

1Amsterdam Medical Center, Tytgat institute for liver and intestinal research, Amsterdam, Netherlands, 2Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands, 3Academic Medical Center, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands

DOP085.

Success rate of dose de-escalation in patients with inflammatory bowel disease treated with intensified anti-TNF therapy

Authors:

N. Viazis, J. Anastasiou, T. Koukouratos, M. Giakoumis, E. Anastasopoulos, M. Chanias, K. Markoglou, D. Karamanolis, Evangelismos Hospital, Gastroenterology Department, Athens, Greece

DOP085

A candidate gene study of rare monogenic disorders with IBD-like phenotype identified rare variants in XIAP gene in a cohort of early-onset IBD patients

Authors:

L. Amininejad*1, B. Charloteaux2, E. Théâtre2, J. Van Cauter3, P. Hayard3, V. Muls4, J.M. Maisin5, M. Schapira5, J.-M. Ghislain5, P. Closset6, M. Talib7, M. Abramowicz8, M. Mni2, L. Karim2, N. Cambisano2, J. Devière1, M. De Vos9, E. Louis10, S. Vermeire11, A. Van Gossum1, W. Coppieters2, M. Georges2, D. Franchimont1

1Erasme Hospital, Université Libre de Bruxelles, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology and Laboratory of Experimental Gastroenterology, Brussels, Belgium, 2Groupe Interdisciplinaire de génoprotéomique Appliquée (GIGA-R) and Faculty of veterinary medicine, University of Liège (B34), Unit of Animal Genomic, Liège, Belgium, 3Charleroi University Hospital, Department of Gastroenterology, Charleroi, Belgium, 4Saint Pierre Hospital, Department of Gastroenterology, Brussels, Belgium, 5Jolimont Hospital, Department of Gastroenterology, La Louvière, Belgium, 6Ixelles Hospital, Department of Gastroenterology, Brussels, Belgium, 7Brugmann Hospital, Department of Gastroenterology, Brussels, Belgium, 8Erasme Hospital, Université Libre de Bruxelles, Department of Human Genetics, Brussels, Belgium, 9Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent, Belgium, 10Sart Tilman Hospital, University of Liège (B34), Department of Gastroenterology, Liège, Belgium, 11KU Leuven, Department of Clinical and Experimental Medecine, Gastroenterology section, Leuven, Belgium

DOP086.

Intestinal resection in Crohn's disease is associated with significant and durable improvement in health related quality of life although to a lesser extent in women and smokers. Results from the POCER study

Authors:

E.K. Wright, P.P. De Cruz, M.A. Kamm, A.L. Hamilton, K.J. Ritchie, E.O. Krejany, A. Gorelik, D. Liew, L. Prideaux, I.C. Lawrance, J.M. Andrews, P.A. Bampton, S.L. Jakobovits, T.H. Florin, P.R. Gibson, H.S. Debinski, A.S. Day, R.B. Gearry, F.A. Macrae, D. Samuel, R.W. Leong, I.J. Kronborg, G.L. Radford-Smith, W.S. Selby, M.J. Johnson, R.J. Woods, P.R. Elliott, S.J. Bell, S.J. Brown, W.R. Connell, P.V. Desmond, St Vincent's Hospital & University of Melbourne, Gastroenterology, Melbourne, Australia

DOP086

Enteric micriobiota alterations in patients with a normal ileal pouch may be predictive of pouchitis

Authors:

N. Maharshak*1, L. Reshef2, O. Davidov1, H. Tulchinsky3, U. Gophna2, I. Dotan1

1Tel Aviv Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 2Tel Aviv University, Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Proctology Unit, Department of Surgery, Tel Aviv, Israel

DOP087.

Only one third of Crohn's disease patients have sustained remission of perianal fistulas

Authors:

I. Molendijk1, V.J. Nuij2, A.E. van der Meulen-de Jong1, C.J. van der Woude2, 1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands

DOP087

Intestinal microbial signature in patients with primary sclerosing cholangitis

Authors:

J. Sabino*1, S. Vieira-Silva2, 3, K. Machiels1, M. Joossens2, 3, 4, G. Falony2, 3, V. Ballet1, M. Ferrante1, G. Van Assche1, S. Van Der Merwe5, J. Raes2, 3*, S. Vermeire1*

1KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID), Leuven, Belgium, 2REGA institute, KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium, 3Vlaams Instituut voor Biotechnologie (VIB), Center for the Biology of Disease, Leuven, Belgium, 4VUB, Department of Microbiology, Brussels, Belgium, 5University Hospitals of Leuven, Department of Hepatology, Leuven, Belgium, *Contributed equally as joint last authors

DOP088.

Defunctioning ileostomy does not prevent anastomotic leaks after restorative procto­colectomy with ileal pouch-anal anastomosis in patients treated with anti-TNF and steroids

Authors:

S. Sahami1, C. Buskens1, T. Young-Fadok2, A. de Buck van Overstraeten3, A. D'Hoore3, W. Bemelman1, 1Academic Medical Center, Surgery, Amsterdam, Netherlands, 2Mayo Clinic, Surgery, Phoenix, United States, 3University of Leuven, Surgery, Leuven, Belgium

DOP088

Changes in faecal microbiota in UC patients after Faecal Microbiota Transplantation

Authors:

N. Rossen*1, S. Fuentes2, M. van der Spek1, J. Hartman2, W. de Vos2, G. D'haens1, E. Zoetendal2, C. Ponsioen1

1Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands, 2Wageningen University, Laboratory of Microbiology, Wageningen, Netherlands

DOP089.

Measurement of IBD disease activity using home-based e-health technologies

Authors:

W. van Deen, J. Choi, A. Zand, C. Ha, E. Inserra, L. Eimers, A. Centeno, B. Roth, D. Cole, T. Getzug, E. Kane, L. Connoly, M. Ovsiowitz, A. Ho, M. van Oijen, E. Esrailian, D.W. Hommes, UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, Los Angeles, United States

DOP089

Comparative genome analysis of Crohn's Disease-associated adherent, invasive Escherichia coli fails to detect a common molecular property

Authors:

C. O'Brien*1, 2, P. Pavli1, 2, D. Gordon3, K. Holt4, A. Dubois5, A. Darfeuille-Michaud5, M. Agnes-Bringer5

1Australian National University, Medical School, Canberra, ACT, Australia, 2Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, ACT, Australia, 3Australian National University, Research School of Biology, Canberra, ACT, Australia, 4University of Melbourne, Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, Melbourne, Australia, 5University of Auvergne, Pathogenie Bacterienne Intestinale, Clermont-Ferrand, France

DOP090.

Results from a feasibility study with the telemedicine tool myIBDcoach in the Netherlands

Authors:

J. Degens1, M. Romberg-Camps2, M. Cilissen3, H. Tomlow3, T. Markus4, A. Masclee3, D. Jonkers3, A. van der Meulen-de Jong5, M. Pierik6, 1MUMC, division Gastroenterology-Hepatology, Maastricht, Netherlands, 2ORBIS Medical Centre, Gastroenterology and Hepatology, Sittard, Netherlands, 3MUMC, Gastroenterology, Maastricht, Netherlands, 4CCUVN, CCUVN, Hoofddorp, Netherlands, 5Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 6Maastricht University Medical Centre, Internal Medicine – Division of Gastroenterology and Hepatology, Maastricht, Netherlands

DOP090

Dysbiosis of oral microbiome in adult Chinese patients with active Inflammatory Bowel Diseases

Authors:

N. Chen*1, L. Liu2, H. Zheng2, J. Zhang2, J. Lin2, F. Chen3

1Peking University People's Hopital, The Department of Gastroenterology, Beijing, China, 2Peking University School and Hospital of Stomatology, The Department of Orthodontics, Beijing, China, 3Peking University School and Hospital of Stomatology, Central Laboratory, Beijing, China

DOP091.

Intestinal Epstein–Barr virus is associated with mucosal lymphoproliferation and subsequent intestinal surgery in inflammatory bowel disease patients

Authors:

L.H. Nissen1, D.J. de Jong1, I.D. Nagtegaal2, W. Kievit1, M.G. Lynch2, J.H.J. van Krieken2, F. Hoentjen1, 1Radboud UMC, Gastroenterology & Hepatology, Nijmegen, Netherlands, 2Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, Netherlands

DOP092.

Risk of invasive pneumococcal infection in patients with inflammatory bowel disease: A nationwide Danish cohort study

Authors:

B. Kantsø1, J. Simonsen2, S. Hoffmann3, P. Valentiner-Branth4, A. Munk Petersen5, T. Jess2, 1Statens Serum Institut, Microbiological Diagnostics & Virology, Copenhagen, Denmark, 2Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark, 3Statens Serum Institut, Neisseria and Streptococcus Reference Laboratory, Copenhagen, Denmark, 4Statens Serum Institut, Department of Infectious Disease Epidemiology, Copenhagen, Denmark, 5Hvidovre Hospital, Department of Gastroenterology, Hvidovre, Denmark

DOP093.

Characterisation of incident cases of cancer in inflammatory bowel disease: A prospective multicenter matched-pair IG-IBD study

Authors:

L. Biancone1, C. Petruzziello1, A. Armuzzi2, M.L. Scribano3, R. D'Incà4, C. Papi5, L. Spina6, L. Guidi2, A. Kohn3, E. Calabrese1, G. Condino1, S. Onali1, F. Mocciaro7, R. Monterubbianesi3, P. Alvisi8, W. Fries9, G. Riegler10, F. Castiglione11, I. Frankovic4, G. Margagnoni5, R. Di Mitri7, G. Meucci12, F. Rogai13, S. Ardizzone14, A. Orlando15, F. Pallone1, 1Università di Roma Tor Vergata, Medicina dei sistemi, cattedra di Gastroenterologia, Roma, Italy, 2Università Cattolica, CIC, Roma, Italy, 3A.O.San Camillo Forlanini, Gastroenterology Unit, Rome, Italy, 4University of Padova, Gastroenterology Department, Padova, Italy, 5AO S. Filippo Neri, UOC GE/Hep, Roma, Italy, 6Università S. Donato, Gastroenterologia, Milano, Italy, 7ARNAS Civico-Di Cristina-Benfratelli Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy, 8Ospedale Maggiore, Pediatria, Bologna, Italy, 9Università di Messina, Medicina Interna, Messina, Italy, 10Seconda Università Napoli, SUN, Napoli, Italy, 11Università “Federico II” di Napoli, Gastroenterologia, Napoli, Italy, 12S. Giuseppe Hospital, Gastroenterology, Milano, Italy, 13AOU Careggi, Largo Brambilla, Gastroenterologia, Firenze, Italy, 14Luigi Sacco University Hospital, Gastroenterology Department, Milano, Italy, 15Ospedale Cervello, Medicina Interna, Palermo, Italy

DOP094.

Cancer in elderly-onset inflammatory bowel disease: A population-based study

Authors:

H. Cheddani1, L. Dauchet2, C. Charpentier1, M. Fumery3, J. Salleron4, A.-M. Bouvier5, J.-L. Dupas3, F. Vasseur2, E. Lerebours1, L. Armengol-Debeir1, E. Laberenne6, L. Peyrin-Biroulet7, J.-F. Colombel8, G. Savoye1, C. Gower-Rousseau2,9, 1University and Hospital, Gastroenterology, Rouen, France, 2University and Hospital, Epidemiology, Lille, France, 3University and Hospital, Gastroenterology, Amiens, France, 4University and Hospital, Biostatistics EA 2694, Lille, France, 5Francim Registry, Public Health, Dijon, France, 6Hospital, Gastroenterology, Seclin, France, 7University and Hospital, Gastroenterology, Nancy, France, 8Hemsley Inflammatory Bowel Disease Center, Icahn Medical School of Medicine at Mount Sinai, New-York, United States, 9Health, Epidemiology, Lille, France

DOP095.

Five-year safety results from the ENCORE registry: Malignancies in patients with Crohn's disease treated with infliximab, standard therapy, or switched from standard therapy to infliximab

Authors:

G. D'Haens1, W. Reinisch2, J.-F. Colombel3, J. Panes4, S. Ghosh5, C. Prantera6, S. Lindgren7, D.W. Hommes8, Z. Huang9, S. Huyck10, D.K. Chitkara11, 1Academic Medical Center, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 2Medical University, Department of Internal Medicine III, Vienna, Austria, 3Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States, 4Hospital Clinic I Provincial, Department of Inflammatory Disease, Barcelona, Spain, 5University of Calgary, Department of Medicine, Calgary, Canada, 6AO San Camillo Forlianini, Gastroenterology Operative Unit, Rome, Italy, 7University Hospital MAS, Department of Gastroenterology, Malmö, Sweden, 8University of California Los Angeles, Center for Inflammatory Bowel Diseases, Los Angeles, United States, 9Merck Sharp & Dohme, Department of Epidemiology, Kenilworth, United States, 10Merck Sharp & Dohme, Department of Statistics, Merck Research Laboratories, Kenilworth, United States, 11Merck Sharp & Dohme, Department of Clinical Research, Kenilworth, United States

DOP096.

Risk of dysplasia and cancer complicating colonic strictures in inflammatory bowel disease: a GETAID study

Authors:

M. Fumery1, A. Amiot2, X. Hebuterne3, S. Nancey4, V. Abitbol5, C. Stefanescu6, J.-P. Le Mouel1, A. Bressenot7, Y. Bouhnik6, L. Peyrin-Biroulet7, 1CHU Amiens, Gastroenterologie France, 80, Amiens, France, 2Hôpital Henri-Mondor, Gastroenterologie, Creteil, France, 3CHU de Nice, Gastroenterologie, Nice, France, 4Hospices Civils de Lyon, Lyon-Sud hospital, Gastroenterology, Pierre Benite, France, 5Hôpital Cochin, Gastroenterology, Paris, France, 6Hopital Beaujon – APHP, Gastroenterologie, Clichy, France, 7CHU de Nancy, Gastroenterologie, Vandoeuvre-les-Nancy, France